Cargando…

Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group

INTRODUCTION: Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant genetic disorders. Some clinical manifestations are present at birth, while some develop during childhood, and others can occur at any age. Given the early age at which patients develop clinical features, diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Alessandra, Geller, Mauro, Mezitis, Spyros, Rubenstein, Allan E, Oliveira, Lisa, Medeiros Lima, Daniel JM, Suchmacher Neto, Mendel, Nigri, Rafael, Cunha, Karin Gonçalves Soares, Takirambudde, Sanyu, Gonçalves Ribeiro, Marcia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826272/
https://www.ncbi.nlm.nih.gov/pubmed/35156025
http://dx.doi.org/10.1177/2632010X20928930
_version_ 1784647398017990656
author Santos, Alessandra
Geller, Mauro
Mezitis, Spyros
Rubenstein, Allan E
Oliveira, Lisa
Medeiros Lima, Daniel JM
Suchmacher Neto, Mendel
Nigri, Rafael
Cunha, Karin Gonçalves Soares
Takirambudde, Sanyu
Gonçalves Ribeiro, Marcia
author_facet Santos, Alessandra
Geller, Mauro
Mezitis, Spyros
Rubenstein, Allan E
Oliveira, Lisa
Medeiros Lima, Daniel JM
Suchmacher Neto, Mendel
Nigri, Rafael
Cunha, Karin Gonçalves Soares
Takirambudde, Sanyu
Gonçalves Ribeiro, Marcia
author_sort Santos, Alessandra
collection PubMed
description INTRODUCTION: Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant genetic disorders. Some clinical manifestations are present at birth, while some develop during childhood, and others can occur at any age. Given the early age at which patients develop clinical features, diagnosis is often made during childhood. The most prevalent features of NF1 are café au lait spots, dermal and plexiform neurofibromas, and learning disability. A variety of skeletal problems may be seen in NF1, including scoliosis, short stature, and pseudoarthrosis. Reduced skeletal bone mass has been documented to be a common phenomenon in children and adults with NF1. Decreased serum 25-hydroxyvitamin D (vitamin D) levels have been noted in adults and children with NF1 and have been reported to be inversely correlated with the number of dermal neurofibromas in adults. However, the actual correlation of vitamin D level to bone density and dermal neurofibroma number in children with NF1 remains unclear. OBJECTIVES: The primary objective of this study was to evaluate vitamin D levels among children and adolescents with NF1. The secondary objective was to describe the levels of vitamin D among children and adolescents with NF1, to verify in which age group there is a higher frequency of vitamin D alterations, and to explore vitamin D level correlations between age, gender, sun exposure, number of neurofibromas, and number of plexiform neurofibromas. METHODS: This was an observational, cross-sectional, hospital-based study. We obtained a convenience sample of individuals with confirmed diagnosis of NF1 from patients attending the Medical Genetics Service of the IPPMG-UFRJ and Santa Casa de Misericórdia of Rio de Janeiro over a 24-month period. We evaluated vitamin D levels in blood samples of patients with NF1 by a chemiluminescent immunoassay method, and we correlated the results with gender, age, number of neurofibromas, number of plexiform neurofibromas, and satisfactory sun exposure. RESULTS: Of the 55 patients, 28 (50.9%) were female and 27 (49.1%) were male. Patient ages ranged from a minimum of 1.2 to a maximum of 19.6 years (mean age 10.95 years) and the median was 11.11 years. Median and mean body mass index (BMI; z score) were -0.09 (minimum value -1.63 and maximum of 4.62) and 0.16, respectively. The mean value of vitamin D was 30.82 ng/mL (±12.31) and the median was 29 ng/mL (minimum value of 10.40 ng/mL and maximum of 79.19 ng/mL). CONCLUSIONS: The levels of vitamin D did not differ according to gender, age group, or the presence or number of cutaneous neurofibromas. Among patients with adequate sun exposure, there was a higher incidence of sufficient serum vitamin D levels. Patients with cutaneous neurofibromas in the 0 to 11 age group had a greater tendency to vitamin D sufficiency in relation to patients aged 11 to 19 years.
format Online
Article
Text
id pubmed-8826272
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88262722022-02-10 Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group Santos, Alessandra Geller, Mauro Mezitis, Spyros Rubenstein, Allan E Oliveira, Lisa Medeiros Lima, Daniel JM Suchmacher Neto, Mendel Nigri, Rafael Cunha, Karin Gonçalves Soares Takirambudde, Sanyu Gonçalves Ribeiro, Marcia Clin Pathol Article INTRODUCTION: Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant genetic disorders. Some clinical manifestations are present at birth, while some develop during childhood, and others can occur at any age. Given the early age at which patients develop clinical features, diagnosis is often made during childhood. The most prevalent features of NF1 are café au lait spots, dermal and plexiform neurofibromas, and learning disability. A variety of skeletal problems may be seen in NF1, including scoliosis, short stature, and pseudoarthrosis. Reduced skeletal bone mass has been documented to be a common phenomenon in children and adults with NF1. Decreased serum 25-hydroxyvitamin D (vitamin D) levels have been noted in adults and children with NF1 and have been reported to be inversely correlated with the number of dermal neurofibromas in adults. However, the actual correlation of vitamin D level to bone density and dermal neurofibroma number in children with NF1 remains unclear. OBJECTIVES: The primary objective of this study was to evaluate vitamin D levels among children and adolescents with NF1. The secondary objective was to describe the levels of vitamin D among children and adolescents with NF1, to verify in which age group there is a higher frequency of vitamin D alterations, and to explore vitamin D level correlations between age, gender, sun exposure, number of neurofibromas, and number of plexiform neurofibromas. METHODS: This was an observational, cross-sectional, hospital-based study. We obtained a convenience sample of individuals with confirmed diagnosis of NF1 from patients attending the Medical Genetics Service of the IPPMG-UFRJ and Santa Casa de Misericórdia of Rio de Janeiro over a 24-month period. We evaluated vitamin D levels in blood samples of patients with NF1 by a chemiluminescent immunoassay method, and we correlated the results with gender, age, number of neurofibromas, number of plexiform neurofibromas, and satisfactory sun exposure. RESULTS: Of the 55 patients, 28 (50.9%) were female and 27 (49.1%) were male. Patient ages ranged from a minimum of 1.2 to a maximum of 19.6 years (mean age 10.95 years) and the median was 11.11 years. Median and mean body mass index (BMI; z score) were -0.09 (minimum value -1.63 and maximum of 4.62) and 0.16, respectively. The mean value of vitamin D was 30.82 ng/mL (±12.31) and the median was 29 ng/mL (minimum value of 10.40 ng/mL and maximum of 79.19 ng/mL). CONCLUSIONS: The levels of vitamin D did not differ according to gender, age group, or the presence or number of cutaneous neurofibromas. Among patients with adequate sun exposure, there was a higher incidence of sufficient serum vitamin D levels. Patients with cutaneous neurofibromas in the 0 to 11 age group had a greater tendency to vitamin D sufficiency in relation to patients aged 11 to 19 years. SAGE Publications 2020-10-19 /pmc/articles/PMC8826272/ /pubmed/35156025 http://dx.doi.org/10.1177/2632010X20928930 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Article
Santos, Alessandra
Geller, Mauro
Mezitis, Spyros
Rubenstein, Allan E
Oliveira, Lisa
Medeiros Lima, Daniel JM
Suchmacher Neto, Mendel
Nigri, Rafael
Cunha, Karin Gonçalves Soares
Takirambudde, Sanyu
Gonçalves Ribeiro, Marcia
Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group
title Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group
title_full Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group
title_fullStr Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group
title_full_unstemmed Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group
title_short Determination of Vitamin D Levels in Patients With Neurofibromatosis Type 1 in the Pediatric Age Group
title_sort determination of vitamin d levels in patients with neurofibromatosis type 1 in the pediatric age group
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8826272/
https://www.ncbi.nlm.nih.gov/pubmed/35156025
http://dx.doi.org/10.1177/2632010X20928930
work_keys_str_mv AT santosalessandra determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT gellermauro determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT mezitisspyros determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT rubensteinallane determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT oliveiralisa determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT medeiroslimadanieljm determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT suchmachernetomendel determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT nigrirafael determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT cunhakaringoncalvessoares determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT takirambuddesanyu determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup
AT goncalvesribeiromarcia determinationofvitamindlevelsinpatientswithneurofibromatosistype1inthepediatricagegroup